Health and Social Care Information Centre. Prescription cost analysis fact sheet, England, 2015. Fact sheet. http://www.hscic.gov.uk/catalogue/PUB20200/pres-cost-anal-eng-2015-fact.pdf. Accessed 1 Mar 2018.
NHS Employers. Pharmaceutical services negotiating committee, general practitioners committee. Guidance for the implementation of repeat dispensing: NHS Employers; 2013.
Pharmaceutical Services Negotiating Committee. Medicines wastage and 28 day prescribing guidance. London: Pharmaceutical Services Negotiating Committee; 2007.
NHS Cambridgeshire. Repeat medication for 28 Days. Cambridge: Cambridgeshire Primary Care Trust; 2009.
NHS North East Essex. Prescribing interval policy. Clacton-on-Sea: North East Essex Primary Care Trust; 2010.
NHS Dorset Clinical Commissioning Group. Medicines code chapter 15: policy for repeat prescribing and medication review. Poole: NHS Dorset Clinical Commissioning Group; 2013.
National Audit Office. Prescribing costs in primary care. London: National Audit Office; 2007.
Trueman P, Lowson K, Blighe A, Meszaros A, Wright D, Glanville J, et al. Evaluation of the scale, causes and costs of waste medicines—final report: York Health Economics Consortium and The School of Pharmacy University of London; 2010.
White KG. UK interventions to control medicines wastage: a critical review. Int J Pharm Pract. 2010;18:131–40.
Domino ME, Olinick J, Sleath B, Leinwand S, Byrns PJ, Carey T. Restricting patients’ medication supply to one month: saving or wasting money? Am J Health-Syst Pharm. 2004;61(13):1375–9.
Mitchell AL, Hickey B, Hickey JL, Pearce SH. Trends in thyroid hormone prescribing and consumption in the UK. BMC Public Health. 2009;9:132.
Wong MC, Tam WW, Wang HH, Cheung CS, Tong EL, Cheung N, et al. Duration of initial antihypertensive prescription and medication adherence: A cohort study among 203,259 newly diagnosed hypertensive patients. Int J Cardiol. 2015;182:503–8.
King S, Miani C, Exley J, Larkin J, Kirtley A, Payne RA. The impact of issuing longer versus shorter duration prescriptions: a systematic review. Br J Gen Pract. 2018.
Doble B, Payne R, Harshfield A, Wilson EC. Retrospective, multicohort analysis of the Clinical Practice Research Datalink (CPRD) to determine differences in the cost of medication wastage, dispensing fees and prescriber time of issuing either short (< 60 days) or long (≥ 60 days) prescription lengths in primary care for common, chronic conditions in the UK. BMJ Open. 2017;7(12):e019382.
Batal HA, Krantz MJ, Dale RA, Mehler PS, Steiner JF. Impact of prescription size on statin adherence and cholesterol levels. BMC Health Serv Res. 2007;7:175.
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.
Curtis L, Burns A. Unit Costs of Health and Social Care 2016. Canterbury: Personal Social Services Research Unit, The University of Kent; 2016.
National Institute for Health and Clinical Excellence. Hypertension in adults: diagnosis and management. London: National Institute for Health and Clinical Excellence; 2011.
Hermes M, Gleason PP, Starner CI. Adherence to chronic medication therapy associated with 90-day supplies compared with 30-day supplies. J Manag Care Pharm. 2010;16(2):141–2.
Taitel M, Fensterheim L, Kirkham H, Sekula R, Duncan I. Medication days’ supply, adherence, wastage, and cost among chronic patients in Medicaid. Medicare Medicaid Res Rev. 2012;2(3):E1–13.
NHS Business Services Authority on behalf of the Department of Health. Electronic drug tariff. Part IIIA -Professional Fees (Pharmacy Contractors) August 2016 . London: NHS Business Services Authority; 2016. http://www.drugtariff.nhsbsa.nhs.uk/#/00336026-DD_1/DD00336022/Home. Accessed 1 Aug 2016.
NHS Business Services Authority. Prescription Cost Analysis Data. 2015. http://www.nhsbsa.nhs.uk/PrescriptionServices/3494.aspx. Accessed 1 Aug 2016.
National Collaborating Centre for Mental Health. National Institute for Health and Clinical Excellence. London: The British Psychological Society and The Royal College of Psychiatrists; 2010 (updated 2016).
Pfeiffer PN, Szymanski BR, Valenstein M, McCarthy JF, Zivin K. Trends in antidepressant prescribing for new episodes of depression and implications for health system quality measures. Med Care. 2012;50(1):86–90.
Bhatnagar P, Wickramasinghe K, Williams J, Rayner M, Townsend N. The epidemiology of cardiovascular disease in the UK 2014. Heart. 2015;3:2015.
Elliott RA, Tanajewski L, Gkountouras G, Avery AJ, Barber N, Mehta R, et al. Cost effectiveness of support for people starting a new medication for a long-term condition through community pharmacies: an economic evaluation of the new medicine service (NMS) compared with normal practice. Pharmaco Econ. 2017:1–19.
Parikh S, Dishman B, Smith T. Ninety-day versus thirty-day drug-dispensing systems. Am J Health-Syst Pharm. 2001;58(1):1190–1.
Rabbani A, Alexander GC. Cost savings associated with filling a 3-month supply of prescription medicines. Appl Health Econ Health Policy. 2009;7(4):255–64.
Walton S, Arondekar B, Johnson N, Schumock G. A model for comparing unnecessary costs associated with various prescription fill-quantity policies: illustration using VA data. J Managed Care Pharm. 2001:384–90.
Domino ME, Martin BC, Wiley-Exley E, Richards S, Henson A, Carey TS, et al. Increasing time costs and copayments for prescription drugs: an analysis of policy changes in a complex environment. Health Serv Res. 2011;46(3):900–19.
NHS Choices. NHS in England - help with health costs. 2016. http://www.nhs.uk/NHSEngland/Healthcosts/Pages/Prescriptioncosts.aspx. Accessed Aug 2016.
National Institute for Health and Care Excellence. Type 2 diabetes in adults: management (NG28). London: National Institute for Health and Care Excellence; 2015.
National Institute for Health and Care Excellence. Depression in adults: recognition and management (CG90). London: National Institute for Health and Care Excellence; 2016.
Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Mak. 2002;22(4):340–9.
Sapin C, Fantino B, Nowicki M-L, Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with Major depressive disorder. Health Qual Life Outcomes. 2004;2(1):1–8.
Cipriani A, Furukawa T, Salanti G, Geddes J, Higgins J, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–58.
Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med. 2003;20(6):442–50.
Murphy G, Simons A, Wetzel R, Lustman P. Cognitive therapy and pharmacotherapy. Singly and together in the treatment of depression. Arch Gen Psychiatry. 1984;41(1):33–41.